<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01963585</url>
  </required_header>
  <id_info>
    <org_study_id>0200-11</org_study_id>
    <nct_id>NCT01963585</nct_id>
  </id_info>
  <brief_title>Evaluating the Capacity of High-sensitivity Serum CRP Levels to Predict Bronchial Hyper Responsiveness in School Age Children</brief_title>
  <official_title>Evaluating the Capacity of High-sensitivity Serum CRP Levels to Predict Bronchial Hyper Responsiveness in School Age Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Bronchial hyper responsiveness (BHR) assessed by methacholine challenge test (MCT) may aid in&#xD;
      the diagnosis of asthma, while negative MCT can help to exclude the diagnosis. Laboratory&#xD;
      measures that predict the results of MCT are expected to reduce the number of procedures. The&#xD;
      possible capacity of High sensitive C-reactive protein (hs-CRP), a marker of systemic&#xD;
      inflammation, to predict negative or positive MCT in children has not been evaluated.&#xD;
&#xD;
      Aim: to evaluate the capacity of hs-CRP to predict positive or negative MCT in school aged&#xD;
      children and to compare it with markers of airway inflammation: Fractional exhaled Nitric&#xD;
      Oxide (FeNO) and markers of allergic sensitization (IgE and peripheral blood eosinophils).&#xD;
&#xD;
      Design: Prospective study evaluating these parameters in patients with positive and negative&#xD;
      MCT.&#xD;
&#xD;
      Participant selection: The study population included subjects (age range 6 to 18 years)&#xD;
      referred for Methacholine Challenge Test (MCT)&#xD;
&#xD;
      Sample size: 130 participants in the two groups. Intervention: Each subject will undergo&#xD;
      evaluation including a respiratory questionnaire, methacholine challenge test with&#xD;
      determination of PC20(the provocative concentration that reduced FEV1 by 20% from baseline),&#xD;
      exhaled nitric oxide (eNO). Venous blood will be analyzed for complete blood count +&#xD;
      eosinophils, IGE levels, hs-CRP. All measurements will be evaluated in a single 3 hour visit,&#xD;
      with no follow up study visits.&#xD;
&#xD;
      Primary end point: hs-CRP levels as add on tool to predict negative or positive MCT in&#xD;
      children Secondary outcome parameters: All other parameters are the secondary end points.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HIgh sensitive C-reactive protein</measure>
    <time_frame>participants will be followed for the duration of hospital visit, an average of 3 hours</time_frame>
    <description>in peripheral Blood count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metacholine Challenge Test</measure>
    <time_frame>participants will be followed for the duration of hospital visit, an average of 3 hours</time_frame>
    <description>As assessed by methacholine challenge test with determination of PC20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgE</measure>
    <time_frame>participants will be followed for the duration of hospital visit, an average of 3 hours</time_frame>
    <description>in peripheral Blood count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete blood count</measure>
    <time_frame>participants will be followed for the duration of hospital visit, an average of 3 hours</time_frame>
    <description>in peripheral Blood count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional Exhaled NO</measure>
    <time_frame>participants will be followed for the duration of hospital visit, an average of 3 hours</time_frame>
    <description>determination of exhaled NO in Exhaled breath</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body mass index</measure>
    <time_frame>participants will be followed for the duration of hospital visit, an average of 3 hours</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">131</enrollment>
  <condition>Hyperreactive Airway</condition>
  <arm_group>
    <arm_group_label>Negative metacholine</arm_group_label>
    <description>Healthy control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive metacholine</arm_group_label>
    <description>Hyperreactive airway disease - study group</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        subjects (age range 6 to 18 years) referred for Methacholine Challenge Test (MCT)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age range 6 to 18 years&#xD;
&#xD;
          -  Patient referred for Methacholine Challenge Test (MCT)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Base line FEV1(forced expiratory volume in the first second) &lt; 65%&#xD;
&#xD;
          -  The presence of other systemic or lung disease&#xD;
&#xD;
          -  Anti-inflammatory drugs&#xD;
&#xD;
          -  Upper respiratory tract infection in the last month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>October 13, 2013</study_first_submitted>
  <study_first_submitted_qc>October 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2013</study_first_posted>
  <last_update_submitted>October 13, 2013</last_update_submitted>
  <last_update_submitted_qc>October 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>C reactive protein</keyword>
  <keyword>Airway hyperreactivity</keyword>
  <keyword>Body mass index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchial Hyperreactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

